Found: 68
Select item for more details and to access through your institution.
The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 8, p. 912, doi. 10.1111/head.14797
- By:
- Publication type:
- Article
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 7, p. 859, doi. 10.1111/head.14775
- By:
- Publication type:
- Article
Photophobia is associated with lower sleep quality in individuals with migraine: results from the American Registry for Migraine Research (ARMR).
- Published in:
- Journal of Headache & Pain, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s10194-024-01756-9
- By:
- Publication type:
- Article
Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 4, p. 333, doi. 10.1111/head.14692
- By:
- Publication type:
- Article
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
- Published in:
- Journal of Headache & Pain, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s10194-024-01736-z
- By:
- Publication type:
- Article
Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
- Published in:
- Cephalalgia, 2024, v. 44, n. 2, p. 1, doi. 10.1177/03331024241235156
- By:
- Publication type:
- Article
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
- Published in:
- European Journal of Neurology, 2024, v. 31, n. 2, p. 1, doi. 10.1111/ene.16131
- By:
- Publication type:
- Article
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 8, p. 1135, doi. 10.1111/head.14619
- By:
- Publication type:
- Article
Hemiplegic Migraine.
- Published in:
- Current Neurology & Neuroscience Reports, 2023, v. 23, n. 7, p. 381, doi. 10.1007/s11910-023-01277-z
- By:
- Publication type:
- Article
The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.
- Published in:
- Pain & Therapy, 2023, v. 12, n. 3, p. 655, doi. 10.1007/s40122-023-00501-5
- By:
- Publication type:
- Article
Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 3, p. 322, doi. 10.1111/head.14433
- By:
- Publication type:
- Article
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 3, p. 418, doi. 10.1111/head.14485
- By:
- Publication type:
- Article
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
- Published in:
- Cephalalgia, 2023, v. 43, n. 2, p. 1, doi. 10.1177/03331024221137091
- By:
- Publication type:
- Article
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 2, p. 233, doi. 10.1111/head.14403
- By:
- Publication type:
- Article
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01519-4
- By:
- Publication type:
- Article
Raynaud's phenomenon associated with calcitonin gene‐related peptide receptor antagonists case report.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 10, p. 1419, doi. 10.1111/head.14417
- By:
- Publication type:
- Article
Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Erenumab dosage for migraine prevention: An evidence‐based narrative review with recommendations.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 4, p. 420, doi. 10.1111/head.14266
- By:
- Publication type:
- Article
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 263, doi. 10.1007/s40261-021-01115-5
- By:
- Publication type:
- Article
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Patient preference for early onset of efficacy of preventive migraine treatments.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 3, p. 374, doi. 10.1111/head.14255
- By:
- Publication type:
- Article
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-021-01376-7
- By:
- Publication type:
- Article
Does "wearing off" of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 2, p. 198, doi. 10.1111/head.14257
- By:
- Publication type:
- Article
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
- Published in:
- Cephalalgia, 2022, v. 42, n. 1, p. 3, doi. 10.1177/03331024211042385
- By:
- Publication type:
- Article
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 106, doi. 10.1111/head.14244
- By:
- Publication type:
- Article
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Pharmacovigilance: reporting requirements throughout a product's lifecycle.
- Published in:
- Therapeutic Advances in Drug Safety, 2022, v. 13, p. 1, doi. 10.1177/20420986221125006
- By:
- Publication type:
- Article
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 9, p. 1411, doi. 10.1111/head.14208
- By:
- Publication type:
- Article
Timing and durability of response to erenumab in patients with chronic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 8, p. 1255, doi. 10.1111/head.14193
- By:
- Publication type:
- Article
Cluster Headache: A Review and Update in Treatment.
- Published in:
- Current Neurology & Neuroscience Reports, 2021, v. 21, n. 7, p. 1, doi. 10.1007/s11910-021-01114-1
- By:
- Publication type:
- Article
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 7, p. 1021, doi. 10.1111/head.14153
- By:
- Publication type:
- Article
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 5, p. 766, doi. 10.1111/head.14120
- By:
- Publication type:
- Article
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 10, p. 2444, doi. 10.1111/head.13997
- By:
- Publication type:
- Article
Migraine Treatment in Pregnancy: An American Headache Society Survey.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 10, p. 2594, doi. 10.1111/head.13974
- By:
- Publication type:
- Article
Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01190-7
- By:
- Publication type:
- Article
Non-invasive vagus nerve stimulation for primary headache: A clinical update.
- Published in:
- Cephalalgia, 2020, v. 40, n. 12, p. 1370, doi. 10.1177/0333102420941864
- By:
- Publication type:
- Article
Primary Exercise Headache.
- Published in:
- Current Neurology & Neuroscience Reports, 2020, v. 20, n. 5, p. 1, doi. 10.1007/s11910-020-01028-4
- By:
- Publication type:
- Article
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 5, p. 833, doi. 10.1111/head.13810
- By:
- Publication type:
- Article
Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 4, p. 686, doi. 10.1111/head.13766
- By:
- Publication type:
- Article
The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 2, p. 337, doi. 10.1111/head.13688
- By:
- Publication type:
- Article
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 2, p. 348, doi. 10.1111/head.13691
- By:
- Publication type:
- Article
Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 1, p. 141, doi. 10.1111/head.13682
- By:
- Publication type:
- Article
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 10, p. 1762, doi. 10.1111/head.13642
- By:
- Publication type:
- Article
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
- Published in:
- Journal of Headache & Pain, 2019, v. 20, n. 1, p. N.PAG, doi. 10.1186/s10194-019-1032-x
- By:
- Publication type:
- Article
Neuromodulation for the Acute and Preventive Therapy of Migraine and Cluster Headache.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, p. 33, doi. 10.1111/head.13586
- By:
- Publication type:
- Article